Tags

Type your tag names separated by a space and hit enter

Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.EO

Abstract

INTRODUCTION

Weight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction with a reduced-calorie diet and increased physical activity.

AREAS COVERED

This review describes the pharmacology and clinical trials data for phentermine/topiramate ER and its role in a complications-centric approach to medical care of the overweight and obese patient.

EXPERT OPINION

Phentermine/topiramate ER is an effective and safe weight-loss medication that can produce and sustain approximately 10% loss of body weight. This is a landmark development in the pharmacotherapy of obesity. By offering an effective medical option to complement lifestyle and surgical approaches, phentermine/topiramate ER enables a comprehensive medical model for obesity care. The overall approach to the overweight and obese patient should be to identify individuals who will benefit most from therapy based on cardiometabolic or mechanical complications, establish therapeutic targets and goals for ameliorating these complications and selecting the treatment modality and intensity for weight loss to achieve these goals. This complications-centric model emphasizes weight loss as a tool to ameliorate obesity-related complications and optimizes benefit/risk for achieving the best outcomes in overweight/obese patients.

Authors+Show Affiliations

University of Alabama at Birmingham, Department of Nutritional Sciences , Webb 232, 1720 Second Ave. South, Birmingham, AL 35294-3360, USA. garveyt@uab.edu

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23738843

Citation

Garvey, William Timothy. "Phentermine and Topiramate Extended-release: a New Treatment for Obesity and Its Role in a Complications-centric Approach to Obesity Medical Management." Expert Opinion On Drug Safety, vol. 12, no. 5, 2013, pp. 741-56.
Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013;12(5):741-56.
Garvey, W. T. (2013). Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opinion On Drug Safety, 12(5), 741-56. https://doi.org/10.1517/14740338.2013.806481
Garvey WT. Phentermine and Topiramate Extended-release: a New Treatment for Obesity and Its Role in a Complications-centric Approach to Obesity Medical Management. Expert Opin Drug Saf. 2013;12(5):741-56. PubMed PMID: 23738843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. A1 - Garvey,William Timothy, Y1 - 2013/06/06/ PY - 2013/6/7/entrez PY - 2013/6/7/pubmed PY - 2014/4/3/medline SP - 741 EP - 56 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 12 IS - 5 N2 - INTRODUCTION: Weight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction with a reduced-calorie diet and increased physical activity. AREAS COVERED: This review describes the pharmacology and clinical trials data for phentermine/topiramate ER and its role in a complications-centric approach to medical care of the overweight and obese patient. EXPERT OPINION: Phentermine/topiramate ER is an effective and safe weight-loss medication that can produce and sustain approximately 10% loss of body weight. This is a landmark development in the pharmacotherapy of obesity. By offering an effective medical option to complement lifestyle and surgical approaches, phentermine/topiramate ER enables a comprehensive medical model for obesity care. The overall approach to the overweight and obese patient should be to identify individuals who will benefit most from therapy based on cardiometabolic or mechanical complications, establish therapeutic targets and goals for ameliorating these complications and selecting the treatment modality and intensity for weight loss to achieve these goals. This complications-centric model emphasizes weight loss as a tool to ameliorate obesity-related complications and optimizes benefit/risk for achieving the best outcomes in overweight/obese patients. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/23738843/Phentermine_and_topiramate_extended_release:_a_new_treatment_for_obesity_and_its_role_in_a_complications_centric_approach_to_obesity_medical_management_ L2 - http://www.tandfonline.com/doi/full/10.1517/14740338.2013.806481 DB - PRIME DP - Unbound Medicine ER -